Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90


The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.

Yamane BH, Hank JA, Albertini MR, Sondel PM.

Expert Opin Investig Drugs. 2009 Jul;18(7):991-1000. doi: 10.1517/13543780903048911. Review.


A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM; Children's Oncology Group.

Clin Cancer Res. 2006 Mar 15;12(6):1750-9.


Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma.

Hank JA, Gan J, Ryu H, Ostendorf A, Stauder MC, Sternberg A, Albertini M, Lo KM, Gillies SD, Eickhoff J, Sondel PM.

Clin Cancer Res. 2009 Sep 15;15(18):5923-30. doi: 10.1158/1078-0432.CCR-08-2963. Epub 2009 Sep 8.


Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

Cancer Immunol Immunother. 2013 Aug;62(8):1303-13. doi: 10.1007/s00262-013-1430-x. Epub 2013 May 10.


Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Ribas A, Kirkwood JM, Atkins MB, Whiteside TL, Gooding W, Kovar A, Gillies SD, Kashala O, Morse MA.

J Transl Med. 2009 Jul 29;7:68. doi: 10.1186/1479-5876-7-68.


Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM.

Clin Cancer Res. 2004 Jul 15;10(14):4839-47.


Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM.

J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27.


Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM.

J Clin Oncol. 2010 Nov 20;28(33):4969-75. doi: 10.1200/JCO.2009.27.8861. Epub 2010 Oct 4.


Technology evaluation: EMD-273063, EMD Lexigen.

Niculescu-Duvaz I.

Curr Opin Mol Ther. 2004 Oct;6(5):559-66.


Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.

Reisfeld RA, Gillies SD.

J Clin Lab Anal. 1996;10(3):160-6. Review. No abstract available.


Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.

King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P.

J Clin Oncol. 2004 Nov 15;22(22):4463-73. Epub 2004 Oct 13.


Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.

Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2012 Dec;61(12):2261-71. doi: 10.1007/s00262-012-1286-5. Epub 2012 Jun 8.


Pre-clinical models for immunotherapy of melanoma.

Reisfeld RA.

Prog Clin Biol Res. 1989;288:183-93. Review. No abstract available.


Combination therapy with interleukin-2 and antitumor monoclonal antibodies.

Sondel PM, Hank JA.

Cancer J Sci Am. 1997 Dec;3 Suppl 1:S121-7. Review.


Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.


Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA.

J Natl Cancer Inst. 1997 Nov 5;89(21):1586-94.


Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface.

Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J.

Cancer Immunol Immunother. 2011 Dec;60(12):1789-800. doi: 10.1007/s00262-011-1072-9. Epub 2011 Jul 27.


A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM.

Cancer. 1997 Jul 15;80(2):317-33.


Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma.

Otto M, Barfield RC, Martin WJ, Iyengar R, Leung W, Leimig T, Chaleff S, Gillies SD, Handgretinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8486-91.


Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.

Soiffer RJ, Chapman PB, Murray C, Williams L, Unger P, Collins H, Houghton AN, Ritz J.

Clin Cancer Res. 1997 Jan;3(1):17-24.

Supplemental Content

Support Center